TGFβ, Fibronectin and Integrin α5β1 Promote Invasion in Basal Cell Carcinoma.

Détails

ID Serval
serval:BIB_34EA65EC06C3
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
TGFβ, Fibronectin and Integrin α5β1 Promote Invasion in Basal Cell Carcinoma.
Périodique
The Journal of investigative dermatology
Auteur⸱e⸱s
Kuonen F., Surbeck I., Sarin K.Y., Dontenwill M., Rüegg C., Gilliet M., Oro A.E., Gaide O.
ISSN
1523-1747 (Electronic)
ISSN-L
0022-202X
Statut éditorial
Publié
Date de publication
11/2018
Peer-reviewed
Oui
Volume
138
Numéro
11
Pages
2432-2442
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Résumé
Basal cell carcinoma (BCC) is the most frequent human cancer and is becoming an important health problem in an aging population. Based on their clinical and histological characteristics, thick BCC are typically divided into low-risk nodular and high-risk infiltrative subtypes, although the underlying mechanisms are poorly understood. We have identified molecular mechanisms that explain the aggressiveness of high-risk infiltrative BCC, with a potential direct clinical impact. In this study, we first show that fibroblasts, transforming growth factor-β, and fibronectin are found preferentially in infiltrative human BCC. This allowed us to develop in vivo models for the study of infiltrative BCC, which in turn let us confirm the role of transforming growth factor-β in inducing peritumoral fibronectin deposition and tumor infiltration. We then show that fibronectin promotes adhesion and migration of BCC cell lines through integrin α5β1-mediated phosphorylation of focal adhesion kinase. Fittingly, both inhibition of integrin α5β1 and phospho-focal adhesion kinase prevent fibronectin-induced migration of BCC cells in vitro as well as BCC infiltration in vivo. Altogether, our results open important insights into the pathogenesis of aggressive infiltrative BCC and identify integrin α5β1 or focal adhesion kinase inhibition as promising strategies for the treatment of advanced BCC.
Mots-clé
Animals, Carcinogenesis, Carcinoma, Basal Cell/metabolism, Carcinoma, Basal Cell/pathology, Cell Adhesion, Cell Line, Tumor, Cell Movement, Fibronectins/metabolism, Focal Adhesion Kinase 1/metabolism, Humans, Integrin alpha5beta1/metabolism, Mice, Mice, Inbred C57BL, Neoplasm Invasiveness, Skin Neoplasms/metabolism, Skin Neoplasms/pathology, Transforming Growth Factor beta/metabolism
Pubmed
Web of science
Création de la notice
17/05/2018 18:35
Dernière modification de la notice
24/09/2019 6:11
Données d'usage